The Mosaic Company -- How the Business Works
Mosaic was formed in 2004 from the merger of IMC Global and Cargill's crop nutrition business.
The company operates three reporting segments: Phosphate (largest US producer, Florida and
Louisiana mines, ~6-8% global share), Potash (Saskatchewan mines at Esterhazy, Colonsay, and
Belle Plaine -- top-3 global producer with ~10-13% share), and Mosaic Fertilizantes (Brazil
distribution and production, the company's largest geographic bet at 40% of revenue).
Unlike Nutrien, Mosaic has no ag retail platform and only one of its three legs (potash) sits
inside a true oligopoly -- the other ~78% of revenue is in fragmented or competitive markets
(phosphate vs OCP and China; Brazil vs Yara, ICL, and Chinese imports). FY2025 revenue was
$12.05B (+8.4% YoY) but operating earnings degraded materially in phosphate, the stock trades
at $23.36 (down ~33% from 52w high), and the composite score of 5.10/10 sits below the quality
bar -- a contrarian Watchlist setup with insider cluster buying as the main bull signal.
FY2025 Revenue
$12.05B
+8.4% YoY | Brazil + potash drove growth
Price / Composite Score
$23 / 5.1
WATCHLIST -- contrarian, quality concerns
Global Potash Share
~10-13%
Top 3-4 global; 22% of revenue
Quality Gates
1 of 3
Oligopoly partial, FCF neg, mgmt 36% hit
How Mosaic makes money -- three segments, one real oligopoly
The Mosaic Business Model -- Three Operating Segments (FY2025 Net Sales)
Mosaic Fertilizantes (Brazil)
40% of Revenue
$4.8B Net Sales | +9% YoY
Production + distribution | 9MT volumes
Op. earnings $277M | competitive market
Q1 2026: $442M Araxa write-down
Phosphate (US)
38% of Revenue
$4.6B Net Sales | +2% YoY
Florida + Louisiana | ~6-8% global share
Op. earnings $135M | -40% YoY
Fragmented vs OCP / China -- challenged
Potash (Canada)
22% of Revenue
$2.7B Net Sales | +12.5% YoY
Esterhazy, Colonsay, Belle Plaine
Op. earnings ~$237M | top-3 oligopoly
Real oligopoly -- supply discipline
Value Chain -- Mine to Farm (No Retail Layer Like NTR)
Mine / Produce
Phosphate (FL/LA) + potash (Saskatchewan) + Brazil
→
Wholesale / Export
Canpotex JV with NTR (potash exports) + direct sales
→
Brazil Distribution
Ports + blending hubs | only direct-to-customer leg
→
Farmers / Co-ops
Large farmers, ag retailers, distributors, co-ops
Potash -- Real Oligopoly
Top 5 (NTR, MOS, Belaruskali, Uralkali, K+S) control ~80% of supply.
$3B+ greenfield costs. Canpotex JV with NTR enforces export discipline.
MOS is #3-4 globally but the legitimate oligopoly leg.
Phosphate -- Fragmented
OCP/Morocco dominates (~25-30%); PhosAgro, Ma'aden, Chinese producers compete.
MOS at only ~6-8% global share. Top 3 control just ~45-50% (below
70% oligopoly threshold). Periodic Chinese export floods compress margins.
Brazil -- Competitive
Mosaic Fertilizantes is large (~15-20% share, top 2-3) but faces Yara,
Nutrien, ICL, Heringer, regional co-ops. Brazil imports 85% of NPK
needs -- MOS competes against direct global imports too.
Only ~22% of revenue (Potash) sits inside a true oligopoly.
The other ~78% lives in concentrated-but-competitive markets where Mosaic captures less
margin upside than oligopolists like NTR potash. There are no real substitutes for potash
or phosphate (no nitrogen substitute either) and the agronomic argument is iron-clad --
but commodity pricing power is weak when oversupply hits, and MOS does not have a retail
moat (no Nutrien-style distribution platform) or a meaningfully scaled proprietary product
layer to capture the food-security tailwind. Mosaic Biosciences is doubling and there is
rare-earth optionality via the Rainbow Rare Earths JV at Uberaba, but both are small
relative to the $12B base. This is the central reason the composite is held to 5.1 vs
NTR's 7.0 -- one good leg, two challenged legs.
Segment data from MOS earnings reports via Daloopa. FY2025 is calendar year ending December 31, 2025.
Segment revenue and operating earnings -- phosphate margin collapse
Net Sales and Operating Earnings by Segment (USD, Calendar Year)
| Segment | FY2024 Sales | FY2025 Sales | % of Total | FY25 Op. Earnings | YoY Sales |
|---|---|---|---|---|---|
| Mosaic Fertilizantes (Brazil) | $4,400M | $4,800M | 39.8% | $277M | +9% |
| Phosphate (US) | $4,510M | $4,600M | 38.2% | $135M | +2% |
| Potash (Canada) | $2,400M | $2,700M | 22.4% | ~$237M | +12.5% |
| Corporate / Eliminations | -- | -- | -- | ($229M) | -- |
| Total | $11,120M | $12,050M | 100% | ~$420M | +8.4% |
Phosphate operating earnings collapsed -40% YoY despite a "tight" market.
Phosphate revenue grew only +2% on flat-to-slightly-up pricing, but operating earnings fell
from $225M in FY2024 to
$135M in FY2025 as
sulfur (input cost spiked to $540-1200/tonne) and ammonia compressed stripping margins.
This is the textbook problem with non-oligopolistic commodity exposure -- when input costs
rise, MOS cannot pass them through with the same discipline NTR's potash franchise can.
Brazil grew sales but Q1 2026 brought the $442M Araxa SSP write-down plus Patos de Minas,
Taquari, and Carlsbad divestitures, signalling a portfolio cleanup amid margin stress.
Potash was the lone bright spot -- volumes and price both up, supply discipline holding.
Financial data from MOS earnings reports via Daloopa. Operating earnings are segment-level; potash op. earnings is an estimate.
Competitive positioning -- one oligopoly leg, two fragmented legs
Market Share by Segment (Oligopoly Gate: PARTIAL PASS -- only potash qualifies)
| Segment / Market | MOS Share | Top Competitors | Structure / Gate |
|---|---|---|---|
| Potash (MOP) | ~10-13% | Nutrien (~20-25%), Belaruskali (~20%), Uralkali (~15%), K+S (~7%) | PASS -- top 5 = ~80%; Canpotex JV w/ NTR |
| Phosphate (DAP/MAP) | ~6-8% | OCP/Morocco (~25-30%), PhosAgro (~10%), Ma'aden, Yunnan/Yuntianhua | FAIL -- top 3 = ~45-50%; China disruptive |
| Brazil NPK Distribution | ~15-20% | Yara, Nutrien, ICL, Heringer, regional co-ops | FAIL -- competitive; 85% of NPK imported |
Optionality and Structural Backdrop
$3B+
Greenfield Potash Mine Cost
No major new projects this decade
2x
Mosaic Biosciences 2026E
8-10 new launches; small base
9MT
Brazil Volumes (2025)
Largest geographic bet
REE
Rainbow JV (Uberaba)
Long-dated optionality
Substitutes and replaceability:
There is no real substitute for potash (potassium is irreplaceable for plant cell function)
and no substitute for phosphate either -- but BUYERS can defer or under-apply for 1-2
seasons, creating the demand destruction MOS keeps citing. MOS is highly substitutable
WITHIN its categories -- DAP from MOS is fungible with DAP from OCP, PhosAgro, or China.
A Brazil buyer could replace MOS supply within 12 months with OCP, PhosAgro, or Chinese
imports. Potash is harder to replace given oligopoly structure but Canpotex-marketed
product is fungible with Nutrien direct sales. MOS is necessary at the SYSTEM level
(US needs domestic phosphate; Brazil needs Mosaic Fertilizantes' blending infrastructure)
but not at the PRODUCT level. The Mosaic Biosciences ramp and Rainbow rare-earth JV are
real options but immaterial to the 12-18 month thesis.
Market share estimates from industry research, MOS investor presentations, and MOS Q1 2026 earnings call commentary.
Key metrics to track -- potash volumes, phosphate margin, Brazil credit
| Metric | FY2024 | FY2025 | Direction | Why It Matters |
|---|---|---|---|---|
| Total Net Sales | $11.12B | $12.05B | +8.4% | Top-line growth from Brazil + potash; phosphate flat |
| Phosphate Op. Earnings | $225M | $135M | -40% | Stripping margin compression; sulfur input cost shock |
| Brazil (MFert) Op. Earnings | ~$210M | $277M | +32% | Still pre-Araxa write-down; Q1 2026 reset incoming |
| Potash Net Sales | $2.4B | $2.7B | +12.5% | Volume + price; oligopoly working as designed |
| Q1 2026 EPS YoY | -- | -89.8% | Trough | Araxa $442M write-down + sulfur drag; reset quarter |
| Brazil Volumes | ~8.5MT | ~9.0MT | +6% | Distribution muscle holding despite credit headwinds |
Key metrics from MOS earnings reports and Q1 2026 transcript via Daloopa.
Structural backdrop -- food security real, but capture is weaker than NTR
Thematic / Structural Tailwinds (Score: 6/10)
Potash Oligopoly + Belarusian Risk
Top 5 control ~80% of supply. Canpotex JV with NTR enforces export discipline.
Belaruskali sanctions remain a structural overhang -- any re-escalation tightens
supply. Q1 2026: Canpotex "fully committed through June and on pace for a record
2026"; China imports set a record; inventories tight through Q2.
Phosphate Tightness -- Cyclical
"Already tight market becoming even tighter" per management. China banned phosphate
exports through August 2026; sulfur shortages forced curtailments. But MOS captured
only $135M in op. earnings (-40% YoY) -- proof that without oligopoly pricing power
input cost shocks eat the upside.
Brazil Growth -- Currently Negative
Long-term: ~5.6% CAGR to $52B by 2031. Near-term: "most complex conditions in
decades" per Q4 2025 -- credit constraints, FX volatility, Chinese DAP/MAP imports
flooding the market. $442M Araxa write-down + Patos/Taquari/Carlsbad divestitures
signal portfolio cleanup amid stress.
Score of 6/10 reflects a soft pass on the oligopoly gate.
MOS has one genuine oligopoly leg (potash, 22% of revenue) that earns the same structural
credit as NTR's potash franchise -- but at half the share, inside a smaller, less-diversified
company. The other ~78% sits in phosphate (globally fragmented, OCP-dominated, China-disruptive)
and Brazil distribution (competitive, mid-cycle weak). The food-security thesis is real but
MOS captures it through commodity volumes rather than proprietary products or a retail moat.
Mosaic Biosciences and rare-earth optionality are real but small. Score is held below NTR's
8 because (a) potash is only 22% of revenue here vs NTR's 37% of EBITDA, (b) phosphate fails
the oligopoly test, (c) Brazil is competitive with negative cyclical momentum, and (d) MOS
lacks NTR's vertical-integration retail moat. Watchlist setup -- contrarian only.
Thematic analysis from MOS screener scoring (March 2026). Demand and inventory data from MOS Q1 2026 earnings call and industry sources.